American Society of Hematology Annual Meeting 2022

The 64th annual 2022 American Society of Hematology (ASH) Annual Meeting takes place in-person in New Orleans, LA, and virtually. The ASH Annual Meeting & Exposition offers educational meetings and workshops for hematology professionals from around the world.

The Mass General Cancer Center will have a strong presence at this year's event, with dozens of leaders scheduled to present their latest hematologic research and lead educational sessions. 

Friday, December 9, 2022

 

Annemarie E. Fogerty, MD

1:30 pm: River City Ballroom (Mardi Gras World)
Session: Blood Buddies: Adult Clinical Classical Hematology (In-Person)

Saturday, December 10, 2022

 

Hanny Al-Samkari, MD

8:00 am: Camp (Hilton New Orleans Riverside)
Session: ITP/TTP—and Other Scary Causes of Thrombocytopenia

David Kuter, MD, DPhil

9:30 am: 291-292
Warm AIHA and the Best Treatment Strategies

Jacob Soumerai, MD

9:30 am: La Nouvelle Orleans Ballroom C
Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination With the BTK Inhibitor Zanubrutinib in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Noopur S. Raje, MD

12:00 pm: R02-R05
Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients With Relapsed or Refractory Multiple Myeloma

Mark B. Leick, MD

2:00 pm: La Nouvelle Orleans Ballroom AB
Patients With Deleterious Germline Variants in STXBP2 Develop Toxicity After CAR-T Cell Therapy With Axicabtagene Ciloleucel

Hanny Al-Samkari, MD

4:00 pm: 243-245
Chemotherapy-Induced Thrombocytopenia

Jeremy S. Abramson, MD

5:30 pm: Hall D
Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) With Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)

Philip Amrein, MD

5:30 pm: Hall D
Phase I Study of Ixazomib With Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Amir Fathi, MD

5:30 pm: Hall D
A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults With Acute Myeloid Leukemia

Patrick Johnson, MD

5:30 pm: Hall D
Longitudinal Patient-reported Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

David Kuter, MD, DPhil

5:30 pm: Hall D
Phase 3, Randomized, Double-blind, Placebo-controlled, Global Study (FORWARD) of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Rachel Rosovsky, MD, MPH

5:30 pm: Hall D
Patients Reporting of Breathlessness After Experiencing Venous Thromboembolic Event

Sunday, December 11, 2022

 

Anna Marneth, PhD

9:30 am: 275-277
Mutant Srsf2 Diminishes Jak2^V617F-Induced Erythrocytosis in Mice and Is Associated With Lower Hemoglobin in Patients With Chronic Phase JAK2-Mutant MPN

Zachariah DeFilipp, MD

12:00 pm: 208-210
Spatial Transcriptomics of Tissue-based Immune Response to Acute Graft-Versus-Host Disease of the Lower Gastrointestinal Tract

Jeremy S. Abramson, MD

4:30 pm: Hall E
Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) With Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) as Second-Line (2L) Treatment in Patients With Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study

Hanny Al-Samkari, MD

4:30 pm: 288-290
A Multicenter Study of Safety, Tolerability, and Effectiveness of Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia

Matthew J. Frigault, MD

6:00 pm: Hall D
Phase 1 Study of CART-Ddbcma for the Treatment of Subjects With Relapsed and /or Refractory Multiple Myeloma

Joan How, MD

6:00 pm: Hall D
Immunologic Responses to SARS-CoV-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations With Infections

David Kuter, MD, DPhil

6:00 pm: Hall D
Clinical Predictors of Response to Rilzabrutinib Therapy in Patients With Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study

David J. Lee, MD, MPH, MMSc

6:00 pm: Hall D
Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa

Orly Leiva, MD

6:00 pm: Hall D
Trends in All-cause and Cardiovascular Mortality Among Patients With Myeloproliferative Neoplasms: A Surveillance, Epidemiology, and End Results Database Analysis

Elizabeth O'Donnell, MD

6:00 pm: Hall D
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Monday, December 12, 2022

 

Yi-Bin Chen, MD

10:30 am: 252-254
RGI-2001 Infusion for Prevention of Acute Gvhd After Allogeneic Hematopoietic Cell Transplantation

Michael Mazzola, BS

2:45 pm: 252-254
Cap-Independent Protein Translation in Hematopoiesis

Bimarzhan Assatova

4:30 pm: 391-392
KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients With Mature T and NK/T-Cell Lymphomas

Rebecca S. Karp Leaf, MD

4:30 pm: 388-390
Clinical Experience With Afamelanotide for the Protoporphyrias in the United States

David Kuter, MD, DPhil

4:30 pm: Great Hall AD
Moving Forward in Hemolytic Anemias: Acquired and Hereditary—Clinical Discussant for Cold Agglutinin Disease

Hanny Al-Samkari, MD

6:00 pm: Hall D
Mitapivat Improves Markers of Hemolysis and Erythropoiesis in Patients With Pyruvate Kinase Deficiency Irrespective of Hemoglobin Response

Leora S. Boussi, MD

6:00 pm: Hall D
Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients With Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Andrew Branagan, MD, PhD

6:00 pm: Hall D
Clinical Effectiveness and Long-term Serologic Responses of COVID-19 Vaccination in Patients With Multiple Myeloma and Waldenström Macroglobulinemia

Tejaswini Dhawale, MD

6:00 pm: Hall D
Perception of Prognosis, Quality of Life, and Distress in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Mihir Gupta, MD

6:00 pm: Hall D
A Rapid Genotyping Assay for CSF Accelerates Diagnosis and Treatment Initiation for CNS Malignancies

Orly Leiva, MD

6:00 pm: Hall D
Risk Factors for Major Adverse Cardiac Events and Bleeding in Patients With Myeloproliferative Neoplasms Admitted for Myocardial Infarction

Daniel Pearson, MD

6:00 pm: Hall D
Use of Clinical Decision Support to Improve the Laboratory Evaluation of Monoclonal Gammopathies

Jacob Soumerai, MD

6:00 pm: Hall D
A Phase 1 Study With the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination With Zanubrutinib (ZANU) in Patients (Pts) With Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data